Results 151 to 160 of about 180,170 (299)

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source

Heparan sulfate and glycomimetics: Advances in synthesis and biological applications for post‐stroke neurorepair

Neuroprotection, EarlyView.
ECM, extracellular matrix; BDNF, brain‐derived neuroptrophic factor; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor. Abstract Heparan sulfate, a structurally diverse glycosaminoglycan that is abundant in the central nervous system (CNS), orchestrates essential processes fundamental to neural plasticity, neurorepair, and ...
Mozammel H. Bhuiyan, Madeleine J. Smith, Simon F. R. Hinkley, Andrew N. Clarkson   +3 more
wiley   +1 more source

Targeting the immunological synapse in multiple myeloma. [PDF]

Discov Oncol
Sumei L, Bahmani F.
europepmc   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma [PDF]

Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival.
International Myeloma Working Group
core  

Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma. [PDF]

EJHaem
Beer SA, Houlston R, Kaiser MF.
europepmc   +1 more source

Multiple myeloma [PDF]

Clinical Medicine, 2001
D, Samson, C, Singer
openaire   +2 more sources

Dehydrocostus Lactone Suppresses Hepatocellular Carcinoma by Inhibiting Protein Tyrosine Kinase‐7 Mediated β‐Catenin Signaling

Phytotherapy Research, EarlyView.
Schematic summary of the experimentally supported mechanism of DHL in hepatocellular carcinoma. Dehydrocostus lactone (DHL), a sesquiterpene lactone derived from Aucklandia lappa, directly engages protein tyrosine kinase 7 (PTK7), as supported by molecular docking, CETSA, and DARTS assays.
Xiwen Fan, Junhui Li, Yu Qiao, Yuwen Zhong, Xuecheng Ge, Yaoshuai Zhang, Zishu Wang, Feng Qian, Weixin Ren   +8 more
wiley   +1 more source

The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. [PDF]

Mol Cancer Ther
Jiang K, Kirchner M, Herzberg F, Zhao Y, Gasper A, Baumgartner F, Jung P, Braune J, Schulze V, Isaakidis K, Mertins P, Krönke J, Wirth M, Keller U, Habringer S.   +14 more
europepmc   +1 more source

Peptide‐based responsive molecular fluorescent probes for precision oncology

Responsive Materials, EarlyView.
Peptide‐based responsive fluorescent probes have emerged as adaptive functional materials for precision tumor theranostics, combining tumor‐selective recognition, programmable stimulus responsiveness, and modular tunability. They enable high‐contrast imaging, intraoperative guidance, real‐time monitoring, and multimodal applications, while next ...
Xing Wang, Wen Liu, Jiahao Zhang, Wanqi Wang, Zhicheng Jin, Yuqi Tang, Quan Li   +6 more
wiley   +1 more source